The presence of fat-enlarged axillary lymph nodes on mammography screening exams is associated with a fourfold higher risk of type 2 diabetes and a 2.6-fold higher risk for cardiovascular disease, according to new research presented at the ARRS Annual Meeting.
Emerging research suggests the detection of fat-enlarged axillary lymph nodes on screening mammography exams may be associated with significantly higher risks of type 2 diabetes (T2DM), cardiovascular disease (CVD), and hypertension (HTN).
In a retrospective study, which garnered Summa Cum Laude honors at the 2024 American Roentgen Ray Society (ARRS) Annual Meeting in Boston, researchers reviewed bilateral mediolateral oblique views from mammography exams for 1,216 women who had cardiovascular risk factors within one year of the mammogram but no known coronary artery disease (CAD) at the time of the mammography screening. The study authors measured the largest visible axillary lymph node and also determined if the patients had any major adverse cardiovascular events (MACEs) within 10 years after the index mammogram.
The researchers found that 19.1 percent of the cohort had fat-enlarged axillary lymph nodes (greater than 20 mm in length) due to an expanded fatty hilium. For these patients, the study authors noted a fourfold higher risk for T2DM, a 2.6-fold higher risk of CVD, and a 2.5-fold higher risk of HTN.
Here one can see a comparison between mammography findings for two women with similar body mass index (BMI). Note the normal axillary lymph nodes in a 63-year-old woman (A) and a fat-enlarged axillary lymph node in a 52-year-old woman (B). New research revealed a fourfold higher risk of type 2 diabetes and a 2.6-fold higher risk for cardiovascular disease in women presenting with fat-enlarged axillary lymph nodes on mammography exams. (Images courtesy of the American Roentgen Ray Society (ARRS).
“Fat-enlarged axillary lymph nodes visualized on screening mammography may increase the ability to identify women who would benefit from CVD risk reduction strategies and more intensive risk assessment with coronary artery CT,” suggested lead study author Jessica Rubino, M.D., who is affiliated with the Dartmouth Hitchcock Medical Center in Lebanon, N.H., and colleagues.
The researchers noted that axillary lymph nodes were visible on 907 of the 1216 mammography exams reviewed in the study (74.6 percent). Emphasizing the wide eligibility for screening mammography for over 75 percent of women in the United States, the study authors emphasized that obtaining cardiovascular risk data from mammograms could have a significant impact in reducing mortality from CVD, the leading cause of death in women.
“If validated in larger studies, incorporating fat-enlarged nodes into CVD risk models has the potential to improve CVD risk stratification without additional cost or additional testing,” posited Rubino and colleagues.
Reference
1. Rubino J, Austin-Strohbehn J, Wang Q, et al. Fat-enlarged axillary lymph nodes on screening mammograms predict cardiometabolic disease and cardiovascular disease risk. Presented at the 2024 American Roentgen Ray Society (ARRS) Annual Meeting in Boston, May 5-9, Boston. Available at: https://apps.arrs.org/MeetingPortal24/ . Accessed May 5, 2024.
Mammography and Breast MRI: Is it Time to Evaluate Strategies as Opposed to Modalities?
July 5th 2024The combination of mammography with breast MRI within 90 days had a 96.2 percent sensitivity in comparison to 48.1 percent for mammography and 79.7 percent for breast MRI performed within 91 to 270 days after index mammography, according to newly published research.
ACR Collaborative Model Leads to 35 Percent Improvement with Mammography Positioning Criteria
July 1st 2024Noting significant variation with facilities for achieving passing criteria for mammography positioning, researchers found that structured interventions, ranging from weekly auditing of images taken by technologists to mechanisms for feedback from radiologists to technologists, led to significant improvements in a multicenter study.